...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinics and research in hepatology and gastroenterology. >Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey
【24h】

Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey

机译：

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Portal hypertension (PHT) and hepatocellular carcinoma (HCC) are two major com-plications of cirrhosis that are closely linked and impact patients prognosis, particularly acute variceal bleeding (AVB). Therefore, PHT screening and AVB prophylaxis are major issues to improve the outcome of the patients, but practices may vary among physicians.Methods: We submitted hepatologists, gastroenterologists and digestive oncologists to a ques-tionnaire of 70 items about PHT screening and management to evaluate their practice. Results: 95 out of 847 physicians responded to the questionnaire (hepatologists 63.2, Oncolo-gists/gastroenterologists 36.8). In patients with advanced HCC, PHT was assessed by endoscopy in 80.0 of cases. HCC progression motivated a new for 12.6 of respondents while no intent to control was declared for 49.5 of them.AVB primary prophylaxis for large size esophageal varices (EV) was impacted by the presence of red marks at endoscopy. In the absence of a red mark, prophylaxis with non-selective beta-blockers (NSSB) was proposed in 70.5 of cases for patients undergoing TKI and 63.2 undergoing Atezolizumab/Bevacizumab, whereas the combination of endoscopic band ligation (EBL) and NSBB was preferred in 41.1 of patients undergoing TKI versus 53.7 undergoing Atezolizumab/ Bevacizumab in case of a red mark.The initiation of a systemic treatment was lower in patients with an history of AVB 6 months (p<0.001).In case of AVB on Atezolizumab/Bevacizumab, 43.2 continued the treatment after regression of EV, 24.2 continued Atezolizumab alone and 14.7 permanently stopped the treatment.Conclusion: Strategies for screening and management of PHT in advanced HCC remain very het-erogeneous among physicians, suggesting the need to improve PHT knowledge and dedicated studies for advanced HCC.(c) 2022 Published by Elsevier Masson SAS.

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号